YNT-185

• Description :

  YNT-185 is a nonpeptide, selective orexin type-2 receptor (OX2R) agonist, with EC50s of 0.028 and 2.75 μM for OX2R and OX1R, respectively. YNT-185 ameliorates narcolepsy-cataplexy symptoms in mouse models[1][2].

• UNSPSC :

  12352005

• Hazard Statement :

  H315, H319, H320

• Target :

  Orexin Receptor (OX Receptor)

• Type :

  Reference compound

• Related Pathways :

  GPCR/G Protein; Neuronal Signaling

• Applications :

  Neuroscience-Neuromodulation

• Field of Research :

  Neurological Disease

• Assay Protocol :

  https://www.medchemexpress.com/ynt-185.html

• Purity :

  98.46

• Solubility :

  DMSO : 100 mg/mL (ultrasonic)

• Smiles :

  O=C(C1=CC(C2=CC=C(OC)C(S(=O)(NC3=CC=CC(NCCNC(C4=CC=CC=C4N(C)C)=O)=C3)=O)=C2)=CC=C1)N(C)C

• Molecular Formula :

  C33H37N5O5S

• Molecular Weight :

  615.74

• Precautions :

  H315, H319, H320

• References & Citations :

  [1]Nagahara T, et al. Design and Synthesis of Non-Peptide, Selective Orexin Receptor 2 Agonists. J Med Chem. 2015;58 (20) :7931-7937.|[2]Irukayama-Tomobe Y, et al. Nonpeptide orexin type-2 receptor agonist ameliorates narcolepsy-cataplexy symptoms in mouse models. Proc Natl Acad Sci U S A. 2017;114 (22) :5731-5736.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  4°C (Powder, protect from light)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  OX2 Receptor

• CAS Number :

  [1804978-81-1]